SCHEMBL5760197

SCHEMBL5760197

COc1cc(OC)cc(N2CCN(C(=O)c3ccn(CCO)c3-c3ccccc3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 3/20 0.47
GAA P10253 1/20 0.47
DRD2 P14416 1/20 0.44
HTR2A P28223 1/20 0.44
THRB P10828 1/20 0.44
SMN1; SMN2 Q16637 6/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPK1 P28482 3/20 0.43
MEN1 O00255 1/20 0.43
GFER P55789 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 2/20 0.42
MAPT P10636 2/20 0.42
TP53 P04637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383507 0.89 ALDH1A1 (0.48) LMNAALDH1A1KDM4EGAADRD2
SCHEMBL6494493 0.87 ALDH1A1 (0.46) LMNAALDH1A1KDM4EGAADRD2
SCHEMBL6494942 0.86 ALDH1A1 (0.51) LMNAALDH1A1KDM4EGAADRD2
SCHEMBL5763806 0.84 ALDH1A1 (0.43) LMNAALDH1A1KDM4EGAADRD2
SCHEMBL1384243 0.82 ALDH1A1 (0.49) LMNAALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL6502509 0.82 USP2 (0.47) LMNAALDH1A1DRD2HTR2AMAPK1
SCHEMBL5762448 0.81 THRB (0.51) LMNAALDH1A1KDM4ETHRBSMN1; SMN2
SCHEMBL5760134 0.80 LMNA (0.46) LMNAALDH1A1KDM4EGAADRD2
SCHEMBL6494963 0.79 DRD2 (0.43) LMNAALDH1A1DRD2MAPK1MEN1
SCHEMBL6497029 0.78 ALDH1A1 (0.51) LMNAALDH1A1KDM4EGAADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC LMNA 3596/4885ALDH1A1 240/4885KDM4E 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.